

CITATION REPORT

List of articles citing

Comparison of statins in hypertriglyceridemia

DOI: 10.1016/s0002-9149(98)00041-1

American Journal of Cardiology, 1998, 81, 66B-69B.

Source: <https://exaly.com/paper-pdf/28950914/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
301	Effects of statins on triglyceride metabolism. <i>American Journal of Cardiology</i> , 1998 , 81, 32B-35B	3	62
300	Efficacy and safety of simvastatin 80 mg/day in hypercholesterolemic patients. The Expanded Dose Simvastatin U.S. Study Group. <i>American Journal of Cardiology</i> , 1998 , 82, 311-6	3	62
299	Cerivastatin in primary hyperlipidemia: a multicenter analysis of efficacy and safety. <i>American Journal of Cardiology</i> , 1998 , 82, 40J-46J	3	28
298	Cerivastatin in the treatment of mixed hyperlipidemia: the RIGHT study. The Cerivastatin Study Group. Cerivastatin Gemfibrozil Hyperlipidemia Treatment. <i>American Journal of Cardiology</i> , 1998 , 82, 47J-51J	3	17
297	Triglyceride as a risk factor for coronary artery disease. <i>American Journal of Cardiology</i> , 1998 , 82, 22Q-25Q		311
296	Hyperlipidemia and diabetes mellitus. 1998 , 73, 969-76		97
295	Clinical positioning of HMG-CoA reductase inhibitors in lipid management protocols. 1998 , 14 Suppl 3, 29-38		5
294	Cerivastatin in primary hyperlipidemia—a multicenter analysis of efficacy and safety. 1998 , 139 Suppl 1, S15-22		16
293	Lipoproteins and atherogenesis. 1998 , 27, 569-84, viii		6
292	Natural statins and stroke risk. 1999 , 99, 185-8		100
291	Treating patients with hypertriglyceridaemia saves lives: triglyceride revisited. 1999 , 15, 65-77		12
290	Dyslipidaemia and cardiovascular risk in diabetes. 1999 , 1, 189-98		24
289	Different effect of simvastatin and atorvastatin on key enzymes involved in VLDL synthesis and catabolism in high fat/cholesterol fed rabbits. 1999 , 127, 1479-85		40
288	Recent developments in the treatment of hypertriglyceridemia. 1999 , 1, 31-7		6
287	Identification and treatment of hypertriglyceridemia as a risk factor for coronary heart disease. 1999 , 1, 233-7		9
286	Effects of high doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I. <i>American Journal of Cardiology</i> , 1999 , 83, 1476-7, A7	3	106
285	Pharmacologic management of triglycerides. 1999 , 22, 1144-8		4

284	High risk strategies for atherosclerosis. 1999 , 286, 31-45		19
283	Effect of NK-104, a new synthetic HMG-CoA reductase inhibitor, on triglyceride secretion and fatty acid oxidation in rat liver. 1999 , 65, 1493-502		7
282	A Pooled Efficacy Analysis of Cerivastatin in the Treatment of Primary Hyperlipidaemia. 1999 , 18, 433-444		9
281	Hypolipidemic effect of NK-104, a potent HMG-CoA reductase inhibitor, in guinea pigs. 1999 , 146, 259-70		60
280	Atherosclerotic disease in non-insulin-dependent diabetes mellitus: role of abnormal lipids and the place for lipid-altering therapies. 1999 , 138, S406-12		2
279	Effects of statins on carotid disease and stroke. 1999 , 10, 535-41		5
278	The Role of Non-High-Density Lipoprotein-Cholesterol in Evaluation and Treatment of Lipid Disorders. 2000 , 85, 2105-2108		
277	Lipid lowering and coronary bypass graft surgery. 2000 , 15, 395-9		24
276	Pravastatin treatment of very low density, intermediate density and low density lipoproteins in hypercholesterolemia and combined hyperlipidemia secondary to the nephrotic syndrome. 2000 , 20, 12-7		10
275	Diabetic dyslipidaemia. 2000 , 2 Suppl 1, S31-6		34
274	Effect of atorvastatin on endothelium-dependent constrictor factors in dyslipidemic rabbits. 2000 , 34, 263-72		15
273	Effects of simvastatin (40 and 80 mg/day) in patients with mixed hyperlipidemia. <i>American Journal of Cardiology</i> , 2000 , 86, 406-11	3	43
272	High-density lipoprotein cholesterol and triglyceride response with simvastatin versus atorvastatin in familial hypercholesterolemia. <i>American Journal of Cardiology</i> , 2000 , 86, 547-9, A9	3	19
271	Evidence that triglycerides are an independent coronary heart disease risk factor. <i>American Journal of Cardiology</i> , 2000 , 86, 943-9	3	350
270	Lipid-altering efficacy and safety of simvastatin 80 mg/day: long-term experience in a large group of patients with hypercholesterolemia. World Wide Expanded Dose Simvastatin Study Group. 2000 , 23, 39-46		30
269	Comparison of the efficacy and tolerability of simvastatin and atorvastatin in the treatment of hypercholesterolemia. 2000 , 23, 682-8		23
268	Hypertriglyceridemia and Coronary Heart Disease. 2000 , 85, 2098-2105		10
267	Random Thoughts and Opinions. 2000 , 85, 2110-2112		0

266	[Diabetic dyslipidemia: clinical significance and therapeutic attitude]. 2000 , 200, 688-90	0
265	Efficacy and safety of cerivastatin 0.8 mg in patients with hypercholesterolaemia: the pivotal placebo-controlled clinical trial. Cerivastatin Study Group. 2000 , 28, 47-68	35
264	Short-term effect of atorvastatin in hypercholesterolaemic renal-transplant patients unresponsive to other statins. 2000 , 15, 1446-9	13
263	Hyperlipidemia: diagnostic and therapeutic perspectives. 2000 , 85, 2089-112	37
262	HDL-cholesterol and the Treatment of Coronary Heart Disease: Contrasting Effects of Atorvastatin and Simvastatin. 2000 , 16, 139-146	48
261	Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: Recommendations of the Adult AIDS Clinical Trial Group Cardiovascular Disease Focus Group. 2000 , 31, 1216-24	150
260	Statins: effective antiatherosclerotic therapy. 2000 , 139, 577-83	131
259	Familial hypercholesterolaemia. 2000 , 4, 192-197	1
258	Current perspectives on the management of hypertriglyceridemia. 2000 , 140, 232-40	37
257	Atorvastatin and the plasma activities of lipoprotein lipase, hepatic lipase and lecithin:cholesterol acyltransferase in patients with mixed hyperlipidemia. 2000 , 11, 33-38	3
256	Preventing, stopping, or reversing coronary artery disease--triglyceride-rich lipoproteins and associated lipoprotein and metabolic abnormalities: the need for recognition and treatment. 2000 , 46, 421-503	5
255	Attaining United States and European Guideline LDL-cholesterol Levels with Simvastatin in Patients with Coronary Heart Disease (the GOALLS Study). 2000 , 16, 208-219	16
254	Current perspectives on statins. 2000 , 101, 207-13	958
253	Management of hypercholesterolemia. 2000 , 84, 23-42	45
252	Short- and long-term effects of atorvastatin, lovastatin and simvastatin on the cellular metabolism of cholesteryl esters and VLDL secretion in rat hepatocytes. 2000 , 153, 283-94	47
251	Effects of simvastatin and atorvastatin administration on insulin resistance and respiratory quotient in aged dyslipidemic non-insulin dependent diabetic patients. 2000 , 150, 121-7	157
250	Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia. 2001 , 61, 1835-81	111
249	Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner. 2001 , 158, 183-93	149

248	The influence of simvastatin on lipase and cholesterol esterase activity in the serum of men with coronary heart disease. 2001 , 43, 359-62		11
247	Efficacy and tolerability of fluvastatin extended-release delivery system: a pooled analysis. 2001 , 23, 177-92		64
246	HMG-CoA reductase inhibitors. 2001 , 56, 77-114		31
245	Effect of atorvastatin treatment on lipoprotein lipase mass in the pre-heparin plasma in Japanese hyperlipidemic subjects. 2001 , 314, 261-4		17
244	Effects of atorvastatin 10 mg and simvastatin 20 mg on serum triglyceride levels in patients with hypercholesterolemia. 2001 , 62, 408-415		4
243	MANAGEMENT OF HYPERCHOLESTEROLEMIA. 2001 , 19, 295-310		1
242	Drug treatment of combined hyperlipidemia. 2001 , 1, 327-36		18
241	Hypertriglyceridemia: associated risks and effect of drug treatment. 2001 , 1, 455-66		14
240	A randomized, double-blind, placebo-controlled, 8-week study to evaluate the efficacy and safety of once daily atorvastatin (10 mg) in patients with elevated LDL-cholesterol. 2001 , 42, 725-38		19
239	Treatment of mixed hyperlipidaemia using a combination of omega-3 fatty acids and HMG CoA reductase inhibitor. 2001 , 3, D53-D58		9
238	Current Lipid-lowering Strategies for the Treatment of Diabetic Dyslipidemia: An Integrated Approach to Therapy. 2001 , 11, 368-383		3
237	Paraoxonase genotype modifies the effect of pravastatin on high-density lipoprotein cholesterol. 2001 , 11, 625-33		45
236	Targeting triglycerides as prognostic indicators and determining lowest values for patient benefit. 2001 , 3, 424-32		3
235	Hypertriglyceridemia: new insights and new approaches to pharmacologic therapy. <i>American Journal of Cardiology</i> , 2001 , 87, 1174-80; A4	3	45
234	What are the priorities for managing cholesterol effectively?. <i>American Journal of Cardiology</i> , 2001 , 88, 21F-4F	3	4
233	Developing a clinical strategy for cholesterol management in an era of unanswered questions. <i>American Journal of Cardiology</i> , 2001 , 88, 25F-30F	3	2
232	Effect of atorvastatin, simvastatin, and lovastatin on the metabolism of cholesterol and triacylglycerides in HepG2 cells. 2001 , 62, 1545-55		73
231	Squalene synthase inhibitors reduce plasma triglyceride through a low-density lipoprotein receptor-independent mechanism. 2001 , 431, 345-52		25

230	Treating dyslipidaemia in non-insulin-dependent diabetes mellitus -- a special reference to statins. 2001 , 15, 211-26	23
229	Lipid modulation in insulin-dependent diabetes mellitus: effect on microvascular outcomes. 2001 , 15, 113-9	64
228	Statins: mechanism of action and effects. 2001 , 5, 378-87	461
227	Effect of statin therapy on remnant lipoprotein cholesterol levels in patients with combined hyperlipidemia. 2001 , 21, 2026-31	54
226	Elevated baseline triglyceride levels modulate effects of HMGCoA reductase inhibitors on plasma lipoproteins. 2001 , 6, 47-56	9
225	Hypertriglyceridemia: A Review of Clinical Relevance and Treatment Options: Focus on Cerivastatin. 2001 , 17, 60-73	21
224	The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia. 2001 , 24, 1335-41	113
223	Pharmacology of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins), including rosuvastatin and pitavastatin. 2002 , 42, 835-45	64
222	Long term efficacy and safety of atorvastatin in the treatment of severe type III and combined dyslipidaemia. 2002 , 88, 234-8	15
221	Aggressive lipid lowering does not improve endothelial function in type 2 diabetes: the Diabetes Atorvastatin Lipid Intervention (DALI) Study: a randomized, double-blind, placebo-controlled trial. 2002 , 25, 1211-6	86
220	Effect of apolipoprotein E, peroxisome proliferator-activated receptor alpha and lipoprotein lipase gene mutations on the ability of fenofibrate to improve lipid profiles and reach clinical guideline targets among hypertriglyceridemic patients. 2002 , 12, 313-20	63
219	Effects of atorvastatin on postprandial plasma lipoproteins in postinfarction patients with combined hyperlipidaemia. 2002 , 162, 163-70	24
218	Influence of atorvastatin and simvastatin on apolipoprotein B metabolism in moderate combined hyperlipidemic subjects with low VLDL and LDL fractional clearance rates. 2002 , 164, 129-45	72
217	Comparison of the effects of atorvastatin or fenofibrate on nonlipid biochemical risk factors and the LDL particle size in subjects with combined hyperlipidemia. 2002 , 144, G1-G8	10
216	High-density lipoprotein cholesterol and triglycerides as therapeutic targets for preventing and treating coronary artery disease. 2002 , 144, S33-42	87
215	Baseline lipid values partly determine the response to high-dose simvastatin in patients with familial hypercholesterolemia. The examination of probands and relatives in Statin studies with familial hypercholesterolemia (ExPRESS FH). 2002 , 164, 347-54	15
214	[Diabetic dyslipidemia: assessment and treatment]. 2002 , 119, 260-4	2
213	Clinical effects of rosuvastatin, a new HMG-CoA reductase inhibitor, in Japanese patients with primary hypercholesterolemia: an early phase II study. 2002 , 9, 48-56	19

212	Effect of pravastatin on apolipoproteins B and C-III in very-low-density lipoproteins and low-density lipoproteins. <i>American Journal of Cardiology</i> , 2002 , 90, 165-7	3	11
211	Factors affecting low-density lipoprotein and high-density lipoprotein cholesterol response to pravastatin in the West Of Scotland Coronary Prevention Study (WOSCOPS). <i>American Journal of Cardiology</i> , 2002 , 90, 731-6	3	49
210	Use of combination therapy for dyslipidemia: a lipid clinic approach. <i>American Journal of Cardiology</i> , 2002 , 90, 44K-49K	3	9
209	Safety and efficacy of simvastatin in hypercholesterolemic patients undergoing chronic renal dialysis. 2002 , 39, 283-90		66
208	High doses of atorvastatin and simvastatin induce key enzymes involved in VLDL production. 2002 , 37, 445-54		43
207	Lipoprotein changes with statins. 2002 , 4, 14-8		7
206	Triglyceride, but not total cholesterol or low-density lipoprotein cholesterol levels, predict development of proteinuria. 2002 , 62, 1743-9		76
205	Evaluation and management of dyslipidemia in patients with HIV infection. 2002 , 17, 797-810		54
204	Factorial study of the effects of atorvastatin and fish oil on dyslipidaemia in visceral obesity. 2002 , 32, 429-36		72
203	Statins and the role of nitric oxide in chronic heart failure. 2003 , 8, 99-106		56
202	Effects of simvastatin, an HMG-CoA reductase inhibitor, in patients with hypertriglyceridemia. 2003 , 26, 18-24		25
201	Time-dependent lipid response on fluvastatin therapy of patients with hypercholesterolemia sensitive to apoE phenotype. 2003 , 40, 237-45		5
200	Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups. <i>American Journal of Cardiology</i> , 2003 , 91, 3C-10C; discussion 10C	3	110
199	The lipid and non-lipid effects of statins. 2003 , 99, 95-112		200
198	YM-53601, a novel squalene synthase inhibitor, suppresses lipogenic biosynthesis and lipid secretion in rodents. 2003 , 139, 140-6		18
197	Management of dyslipidemias in the age of statins. 2003 , 30, 641-69		2
196	Effect of xuezhikang, a cholestin extract, on reflecting postprandial triglyceridemia after a high-fat meal in patients with coronary heart disease. 2003 , 168, 375-80		36
195	Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. 2003 , 37, 418-27		492

194	Phenotype-dependent and -independent actions of rosuvastatin on atherogenic lipoprotein subfractions in hyperlipidaemia. 2003 , 171, 245-53	84
193	Comparison of treatment with fluvastatin extended-release 80-mg tablets and immediate-release 40-mg capsules in patients with primary hypercholesterolemia. 2003 , 25, 904-18	15
192	Effects of statins on lipoprotein fractions. 2003 , 1253, 247-252	2
191	Statins and metabolic syndrome. 2003 , 1253, 243-246	3
190	Combination therapy with an HMG-CoA reductase inhibitor and a fibric acid derivative: a critical review of potential benefits and drawbacks. 2003 , 3, 169-78	20
189	Thiazolidinediones and blood lipids in type 2 diabetes. 2003 , 23, 1744-9	149
188	Medical management of hyperlipidemia/dyslipidemia. 2003 , 88, 2445-61	34
187	Efficacy of atorvastatin and gemfibrozil, alone and in low dose combination, in the treatment of diabetic dyslipidemia. 2003 , 88, 3212-7	31
186	Evolution of cholesterol management therapies: exploiting potential for further improvement. 2003 , 10, 275-81	8
185	Effect of atorvastatin on the concentration, relative distribution, and chemical composition of lipoprotein subfractions in patients with dyslipidemias of type IIA and IIB. 2003 , 42, 304-10	15
184	Benefits of aggressive drug therapy. 2003 , 18, 79-84	1
183	A Case of Familial Dysbetalipoproteinemia with Very Low Serum High-Density Lipoprotein-Cholesterol: Response to Atorvastatin Therapy. 2003 , 13, 85-90	
182	Triacylglycerol-rich lipoproteins and the generation of small, dense low-density lipoprotein. 2003 , 31, 1066-9	173
181	Cholesterol-lowering Agents and their Use. 2003 ,	
180	Atorvastatin and pravastatin elevated pre-heparin lipoprotein lipase mass of type 2 diabetes with hypercholesterolemia. 2004 , 11, 341-7	34
179	Comparison of mechanism and functional effects of magnesium and statin pharmaceuticals. 2004 , 23, 501S-505S	48
178	Statins and the Role of Nitric Oxide in Chronic Heart Failure. 2004 , 187-194	1
177	Dyslipidemia and the metabolic syndrome. 2004 , 27, 3009-16	16

176	Comparative effects of lipid-lowering therapies. 2004 , 47, 73-104		83
175	Treatment of type IIb familial combined hyperlipidemia with the combination pravastatin-piperazine sultosilate. 2004 , 496, 205-12		5
174	Long-term cardiovascular risk with protease inhibitors and management of the dyslipidemia. <i>American Journal of Cardiology</i> , 2004 , 94, 901-6	3	26
173	Impact of nonprescriptive factors on low-density lipoprotein cholesterol reduction with statins. <i>American Journal of Cardiology</i> , 2004 , 94, 1310-2	3	2
172	Prevention and treatment of the metabolic syndrome. 2004 , 55, 589-612		109
171	Estatinas: potencia, relaci3n coste-efectividad. Estudio comparativo. 2004 , 30, 142-146		
170	Lipaemia, inflammation and atherosclerosis: novel opportunities in the understanding and treatment of atherosclerosis. 2004 , 64 Suppl 2, 19-41		52
169	An open-label comparison of the effects of simvastatin and niacin alone and combined on the lipid profile and lipoprotein (a) level in an Indian population with dyslipidemia. 2004 , 65, 455-69		2
168	Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia. 2004 , 64, 137-51		97
167	A comparative study of atorvastatin and simvastatin as monotherapy for mixed hyperlipidaemia in Type 2 diabetic patients. 2004 , 66, 97-9		4
166	Effects of atorvastatin on triglyceride-rich lipoproteins, low-density lipoprotein subclass, and C-reactive protein in hemodialysis patients. 2004 , 53, 1113-7		35
165	Dyslipidemia in the metabolic syndrome. 2004 , 2, 3-34		1
164	Phenotypes, genotypes and response to statin therapy. 2004 , 15, 387-92		29
163	Rosuvastatin improves the atherogenic and atheroprotective lipid profiles in patients with hypertriglyceridemia. 2004 , 15, 115-23		54
162	[Pharmacological and pharmacokinetic features and clinical effects of pitavastatin (Livalo Tablet)]. 2004 , 123, 349-62		10
161	Atorvastatin reverses age-related reduction in rat hepatic PPARalpha and HNF-4. 2005 , 145, 853-61		46
160	Extracts of <i>Monascus purpureus</i> beyond statins--profile of efficacy and safety of the use of extracts of <i>Monascus purpureus</i> . 2005 , 11, 309-13		15
159	Treatment with high-dose simvastatin reduces secretion of apolipoprotein B-lipoproteins in patients with diabetic dyslipidemia. 2005 , 46, 2735-44		31

158	Familial hypercholesterolemia and response to statin therapy according to LDLR genetic background. 2005 , 43, 793-801	26
157	Rosuvastatin reduces plasma lipids by inhibiting VLDL production and enhancing hepatobiliary lipid excretion in ApoE*3-leiden mice. 2005 , 45, 53-60	16
156	Diabetes mellitus tipo 2. ¿C�mo tratar la dislipemia diab�tica?. 2005 , 17, 40-51	
155	Effects of high dose of simvastatin on levels of dopamine and its reuptake in prefrontal cortex and striatum among SD rats. 2006 , 408, 189-93	24
154	Efficacy of a low dose of pitavastatin compared with atorvastatin in primary hyperlipidemia: results of a 12-week, open label study. 2006 , 13, 108-13	18
153	Factorial study of the effect of n-3 fatty acid supplementation and atorvastatin on the kinetics of HDL apolipoproteins A-I and A-II in men with abdominal obesity. 2006 , 84, 37-43	82
152	Future approaches to reducing low-density lipoprotein cholesterol. 2006 , 1, 463-476	1
151	Cardioprotective strategies to improve long-term outcomes following coronary artery bypass surgery. 2006 , 21, 198-204	9
150	Statins and the risk of acute pancreatitis: a population-based case-control study. 2006 , 23, 185-90	35
149	Tratamiento de la hipertrigliceridemia: fibratos frente a �cidos grasos omega-3. 2006 , 6, 52D-61D	
148	The metabolic syndrome: prevalence, CHD risk, and treatment. 2006 , 20, 121-32	59
147	Lipid-lowering effects of statins: a comparative review. 2006 , 7, 1701-14	37
146	Omega-3 fatty acid ethyl esters (Omacor�) for the treatment of hypertriglyceridemia. 2007 , 2, 263-270	4
145	Targeting high-density lipoprotein cholesterol in the management of cardiovascular disease. 2007 , 5, 210-6	4
144	The effect of statins on postprandial lipemia. 2007 , 8, 551-60	25
143	Hypertriglyceridemia and cardiovascular risk reduction. 2007 , 29, 763-777	97
142	A 12-week, prospective, open-label analysis of the effect of rosuvastatin on triglyceride-rich lipoprotein metabolism in patients with primary dyslipidemia. 2007 , 29, 1403-14	45
141	Effect of rosuvastatin 5-20mg on triglycerides and other lipid parameters in Japanese patients with hypertriglyceridemia. 2007 , 194, 505-11	23

140	Efficacy and safety of extended-release fluvastatin in Turkish patients with hypercholesterolaemia: TULIPS (Turkish Lipid Study). 2007 , 23, 1093-102		4
139	[Treatment of dislipemia in patients with metabolic syndrome or diabetes mellitus]. 2007 , 128, 786-94		1
138	Comparison of sirolimus and everolimus in their effects on blood lipid profiles and haematological parameters in heart transplant recipients. 2007 , 21, 536-43		60
137	Efficacy of drug therapy in the secondary prevention of cardiovascular disease and stroke. <i>American Journal of Cardiology</i> , 2007 , 99, 1E-35E	3	18
136	Usefulness of atherogenic dyslipidemia for predicting cardiovascular risk in patients with angiographically defined coronary artery disease. <i>American Journal of Cardiology</i> , 2007 , 100, 1511-6	3	53
135	Atorvastatin decreases triacylglycerol-associated risk of vascular events in coronary heart disease patients. 2007 , 42, 999-1009		26
134	The role of triglycerides in cardiovascular risk. 2008 , 10, 505-11		25
133	Human cholesterol metabolism and therapeutic molecules. 2008 , 93, 27-42		83
132	The genetic architecture of fasting plasma triglyceride response to fenofibrate treatment. 2008 , 16, 603-13		28
131	Statins as effectors of key activities involved in apoE-dependent VLDL metabolism: review and hypothesis. 2008 , 48, 70-5		7
130	Baseline triglyceride levels and insulin sensitivity are major determinants of the increase of LDL particle size and buoyancy induced by rosuvastatin treatment in patients with primary hyperlipidemia. 2008 , 590, 327-32		21
129	Investigation and management of hypertriglyceridaemia. 2008 , 61, 1174-83		20
128	Insulin resistance and lipid disorders. 2008 , 3, 651-664		12
127	New approaches in the diagnosis of atherosclerosis and treatment of cardiovascular disease. 2008 , 3, 84-91		9
126	Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes. 2008 , 51, 331-51		31
125	COMPARISON OF EFFICACY AND TOLERABILITY OF ORIGINAL AND GENERIC DRUGS OF SIMVASTATIN IN PATIENTS WITH HYPERLIPIDAEMIA AND HIGH RISK OF ISCHEMIC HEART DISEASE COMPLICATIONS. 2008 , 4, 23-27		
124	Pleiotropic vasoprotective effects of statins: the chicken or the egg?. 2009 , 3, 191-204		8
123	Combination Therapy for Dyslipidemia. 2009 , 352-362		1

122	Effect of some statin group of drugs on the phase profile of liposomal membrane fluorescence anisotropy study. 2009 , 82, 821-830		11
121	Statins. 2009 , 253-280		5
120	Towards companion diagnostics for the management of statin therapy. 2009 , 3, 659-71		
119	Prescription omega-3 acid ethyl esters plus simvastatin 20 and 80 mg: effects in mixed dyslipidemia. 2009 , 3, 33-8		17
118	Triglycerides and vascular risk: insights from epidemiological data and interventional studies. 2009 , 10, 320-7		23
117	Traitements des dyslipidémies: moyens pharmacologiques. Indications et recommandations thérapeutiques. 2010 , 7, 1-11		
116	Colesevelam: an improved bile acid sequestrant for treating hypercholesterolemia and improving diabetes. 2010 , 5, 825-834		1
115	The effects of rosuvastatin on the serum cortisol, serum lipid, and serum mevalonic acid levels in the healthy Indian male population. 2010 , 11, 425-32		11
114	Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia. <i>American Journal of Cardiology</i> , 2010 , 105, 1413-9	3	151
113	Author's reply: Low-dose eicosapentaenoic acid and/or docosahexaenoic acid and triglyceride lowering. 2010 , 68, 569-570		
112	Safe and rapid resolution of severe hypertriglyceridaemia in two patients with intravenous insulin. 2010 , 27, 1080-3		6
111	Safety and efficacy of laropiprant and extended-release niacin combination in the management of mixed dyslipidemias and primary hypercholesterolemia. 2010 , 2, 61-71		4
110	A single nucleotide polymorphism in the 3-hydroxy-3-methylglutaryl-coenzyme A reductase gene (HMGCR) influences the serum triacylglycerol relationship with dietary fat and fibre in the European Prospective Investigation into Cancer and Nutrition in Norfolk (EPIC-Norfolk) study. 2010 , 104, 765-72		5
109	Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER Database. 2010 , 51, 1546-53		160
108	The effect of fibrate-statin combination therapy on cardiovascular events: a retrospective cohort analysis. 2010 , 26, 2141-6		10
107	Apolipoprotein E genotype as a most significant predictor of lipid response at lipid-lowering therapy: mechanistic and clinical studies. 2011 , 65, 597-603		19
106	Reduction of liver fructokinase expression and improved hepatic inflammation and metabolism in liquid fructose-fed rats after atorvastatin treatment. 2011 , 251, 32-40		49
105	Retrospective study on antihyperlipidemic efficacy and safety of simvastatin, ezetimibe and their combination in Korean adults. 2011 , 34, 1331-7		5

104	The role of triglycerides in atherosclerosis. 2011 , 13, 544-52	201
103	Hypertriglyceridaemia in statin-treated type 2 diabetic patients. 2011 , 28, 257-260	1
102	Dyslipidaemia in the metabolic syndrome and type 2 diabetes: pathogenesis, priorities, pharmacotherapies. 2011 , 12, 13-30	50
101	Paradoxical decrease in HDL-cholesterol and apolipoprotein A1 with simvastatin and atorvastatin in a patient with type 2 diabetes. 2011 , 48, 75-8	6
100	Triglycerides: a case for treatment?. 2012 , 27, 398-404	24
99	Diagnosis and treatment of severe hypertriglyceridemia. 2012 , 10, 505-14	23
98	'Triglyceride effect' on the dynamics of plasma lipoproteins and its possible link to atherogenesis. 2012 , 7,	2
97	Rosuvastatin-induced high-density lipoprotein changes in patients who underwent percutaneous coronary intervention for non-ST-segment elevation acute coronary syndrome. 2012 , 60, 383-8	8
96	Inhibition of pro-protein convertase subtilisin kexin 9 [corrected] (PCSK-9) as a treatment for hyperlipidaemia. 2012 , 21, 667-76	30
95	Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. 2012 , 59, 2344-53	415
94	Lipid Management. 2012 , 449-460	
93	Titrating lovaza from 4 to 8 to 12 grams/day in patients with primary hypertriglyceridemia who had triglyceride levels >500 mg/dl despite conventional triglyceride lowering therapy. 2012 , 11, 143	13
92	The effect of a 12-week course of omega-3 polyunsaturated fatty acids on lipid parameters in hypertriglyceridemic adult HIV-infected patients undergoing HAART: a randomized, placebo-controlled pilot trial. 2012 , 34, 67-76	23
91	Postprandial lipoprotein metabolism in familial hypercholesterolemia: thinking outside the box. 2012 , 61, 3-11	17
90	Lipid-lowering agents. 2013 , 18, 401-11	23
89	The nuances of atherogenic dyslipidemia in diabetes: focus on triglycerides and current management strategies. 2013 , 65, 683-90	3
88	Demystifying the management of hypertriglyceridaemia. 2013 , 10, 648-61	75
87	Age, abdominal obesity, and baseline high-sensitivity C-reactive protein are associated with low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B responses to ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome. 2013 , 7, 292-303	13

- 86 What should we do about Hypertriglyceridemia in Coronary Artery Disease Patients?. **2013**, 15, 104-17 5
- 85 Epanova(®) and hypertriglyceridemia: pharmacological mechanisms and clinical efficacy. **2013**, 9, 177-86 10
- 84 Drugs for Elevated Low-Density Lipoprotein Cholesterol. **2013**, 421-433
- 83 High prevalence of metabolic syndrome features in patients previously treated for nonfunctioning pituitary macroadenoma. **2014**, 9, e90602 7
- 82 Nutrients utilization in obese individuals with and without hypertriglyceridemia. **2014**, 6, 790-8 6
- 81 Statins and their role in acute pancreatitis: Case report and literature review. **2014**, 5, 191-5 5
- 80 Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials. **2014**, 35, 2249-59 106
- 79 Reaching hypertriglyceridemia goals. **2014**, 30, 391-3
- 78 Control of very low-density lipoprotein secretion by N-ethylmaleimide-sensitive factor and miR-33. **2014**, 115, 10-22 34
- 77 Genetics and causality of triglyceride-rich lipoproteins in atherosclerotic cardiovascular disease. **2014**, 64, 2525-40 149
- 76 Endothelial Dysfunction and Dyslipidemia in Type 2 Diabetes: Pathogenesis, Significance and Therapy. **2014**, 239-278
- 75 Recent advances in pharmacotherapy for hypertriglyceridemia. **2014**, 56, 47-66 104
- 74 The metabolic and pharmacologic bases for treating atherogenic dyslipidaemia. **2014**, 28, 369-85 23
- 73 Lowering triglycerides to modify cardiovascular risk: will icosapent deliver?. **2015**, 11, 203-9 5
- 72 Contemporary and Novel Therapeutic Options for Hypertriglyceridemia. **2015**, 37, 2732-50 6
- 71 Dyslipidemia in Obesity. **2015**, 1-18
- 70 TLC vs Simvastatin vs Simvastatin and TLC in hypercholesterolemia. **2016**, 46, 344-362 1
- 69 Diabetic Dyslipidemia and Risk of Cardiovascular Disease. **2016**, 643-652

68	Pre-treatment with simvastatin prevents the induction of diet-induced atherosclerosis in a rabbit model. 2016 , 5, 667-674	5
67	Low holo-transcobalamin levels are prevalent in vegetarians and is associated with coronary artery disease in Indian population. 2016 , 21, 436-40	4
66	Progress in the care of common inherited atherogenic disorders of apolipoprotein B metabolism. 2016 , 12, 467-84	22
65	Low simvastatin concentrations reduce oleic acid-induced steatosis in HepG cells: An model of non-alcoholic fatty liver disease. 2016 , 11, 1487-1492	14
64	Dyslipidemia in Obesity. 2016 , 525-540	1
63	The Effect of Branching (Star Architecture) on Poly(d,l-lactide) (PDLLA) Degradation and Drug Delivery. 2017 , 18, 728-739	23
62	The challenges of proprotein convertase subtilisin-kexin-9 inhibitors for lipid guidelines and models of care. 2017 , 28, 470-476	1
61	Activation of hepatic Nogo-B receptor expression-A new anti-liver steatosis mechanism of statins. 2018 , 1863, 177-190	9
60	Pharmacological treatment options for severe hypertriglyceridemia and familial chylomicronemia syndrome. 2018 , 11, 589-598	22
59	A redispersible dry emulsion system with simvastatin prepared via fluid bed layering as a means of dissolution enhancement of a lipophilic drug. 2018 , 549, 325-334	9
58	Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017. 2018 , 17, 83	580
57	Determinants of Achieved LDL Cholesterol and "Non-HDL" Cholesterol in the Management of Dyslipidemias. 2018 , 20, 60	4
56	Effect of Lipid-Testing Interval on Stoke Risk among Newly Diagnosed Dyslipidemia Patients Initiated on Statins. 2019 , 8,	
55	The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk. 2019 , 40, 537-557	109
54	Triglycerides: Emerging Targets in Diabetes Care? Review of Moderate Hypertriglyceridemia in Diabetes. 2019 , 19, 13	14
53	Koumiss consumption modulates gut microbiota, increases plasma high density cholesterol, decreases immunoglobulin G and albumin. 2019 , 52, 469-478	17
52	Fenofibrate therapy to lower serum triglyceride concentrations in persons with spinal cord injury: A preliminary analysis of its safety profile. 2020 , 43, 704-709	4
51	The effect of simvastatin on gene expression of low-density lipoprotein receptor, sterol regulatory element-binding proteins, stearoyl-CoA desaturase 1 mRNA in rat hepatic tissues. 2020 , 1-8	

50	Causes and Consequences of Hypertriglyceridemia. 2020 , 11, 252	46
49	Triglycerides and ASCVD Risk Reduction: Recent Insights and Future Directions. 2020 , 22, 25	17
48	Genetics of Triglyceride-Rich Lipoproteins Guide Identification of Pharmacotherapy for Cardiovascular Risk Reduction. 2021 , 35, 677-690	3
47	Triglycerides and cardiovascular disease. 2021 , 36, 469-477	2
46	2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia: A Report of the American College of Cardiology Solution Set Oversight Committee. 2021 , 78, 960-993	28
45	Cholesterol-Lowering Drugs on Akt Signaling for Prevention of Tumorigenesis. 2021 , 12, 724149	1
44	Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society. 2021 ,	35
43	Advances in lipid-lowering therapy in atherosclerosis. 2001 , 498, 49-58	8
42	Pathophysiology and Management of Dyslipidemias Associated with Insulin-Resistant States. 2021 , 307-322	2
41	The Contribution of Triglycerides and Triglyceride-Rich Lipoproteins to Atherosclerotic Cardiovascular Disease. 2011 , 230-251	1
40	Effets thérapeutiques et pléiotropiques des statines dans la prévention primaire et secondaire de l'athérosclérose. 2001 , 185, 49-62	1
39	Hypertriglyceridemia Is Independently Associated with Renal, but Not Retinal Complications in Subjects with Type 2 Diabetes: A Cross-Sectional Analysis of the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicenter Study. 2015 , 10, e0125512	24
38	Camphene, a Plant Derived Monoterpene, Exerts Its Hypolipidemic Action by Affecting SREBP-1 and MTP Expression. 2016 , 11, e0147117	12
37	Atherogenic dyslipidemia and combination pharmacotherapy in diabetes: recent clinical trials. 2013 , 10, 191-203	9
36	A Brief Review of Cardiovascular Diseases, Associated Risk Factors and Current Treatment Regimes. 2019 , 25, 4063-4084	65
35	Relationship between insulin resistance and effect of atorvastatin in non-diabetic subjects. 2005 , 12, 9-13	7
34	Lipid-Lowering Drugs. 2000 , 155-177	
33	Lipid-Lowering Drugs. 2000 , 215-238	

- 32 Hypertriglyceridemia and low high-density lipoprotein: risks for coronary artery disease?. **2000**, 14, 79-90 ○
- 31 An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia. **2001**, 85, 544-548 ○
- 30 References. **2002**, 106, 3373-3421 1
- 29 Lipid-Lowering Drugs. **2003**, 165-191
- 28 Hypolipidemic Agents and Their Role in the Therapy of Diabetes Mellitus.
- 27 Pharmacological Treatments of Lipid Abnormalities. **2005**, 183-212
- 26 Obesity, Lipids, and Cardiovascular Disease. **2006**, 75-92
- 25 Triglycerides and Risk for Atherosclerotic Disease. **2006**, 341-388
- 24 Drugs for Elevated LDL-Cholesterol. **2007**, 528-539
- 23 The ESCAPE randomized clinical trial: 20-80 mg of Zokor (Simvastatin) in patients with familial hypercholesterolemia in ischemia heart disease. Part 1. Hypolipidemic efficacy, safety and tolerance. **2009**, 15, 543-549
- 22 Drug Therapy and Follow-Up. **2011**, 563-631
- 21 Lipid Management. 68-89
- 20 Therapy and clinical trials. **1998**, 9, 617-8
- 19 Statins and Cholesterol: How Low Can You Go?. **2008**, 179-186
- 18 Benefits & risks of statin therapy for primary prevention of cardiovascular disease in Asian Indians - a population with the highest risk of premature coronary artery disease & diabetes. **2013**, 138, 461-91 13
- 17 The effects of different doses of atorvastatin on serum lipid profile, glycemic control, and liver enzymes in patients with ischemic cerebrovascular accident. **2014**, 10, 298-304 5
- 16 Association of 3-hydroxy-3-methylglutaryl-coenzyme A reductase gene polymorphism with obesity and lipid metabolism in children and adolescents with autism spectrum disorder. **2021**, 1 ○
- 15 Emerging Cholesterol Modulators for Atherosclerotic Cardiovascular Disease.. **2022**, ○

14	Loss of sucrase-isomaltase function increases acetate levels and improves metabolic health in Greenlandic cohorts.. 2021 ,	1
13	Triglycerides: How to Manage Patients with Elevated Triglycerides and When to Refer?. 2022 , 106, 299-312	1
12	Reducing residual cardiovascular risk in Europe: Therapeutic implications of European medicines agency approval of icosapent ethyl/eicosapentaenoic acid.. 2022 , 237, 108172	2
11	Triglyceride-Rich Lipoproteins. 2022 , 227-245	
10	Differentiating EPA from EPA/DHA in cardiovascular risk reduction. 2022 , 17, 100148	
9	Statins and prostate cancerType or hope? The epidemiological perspective.	0
8	Lipid profiles and lifestyle habits of stroke survivors in the east coast region of peninsular Malaysia: Preliminary findings. 026010602210974	
7	Hypertriglyceridaemia: an update. jclinpath-2021-207719	0
6	Recent Updates in Hypertriglyceridemia Management for Cardiovascular Disease Prevention.	1
5	What is really new in triglyceride guidelines?. 2023 , 30, 73-80	0
4	Lipid-lowering Eeficacy and Safety of High Doses of Atorvastatin and Rosuvastatin. 2023 , 63, 59-67	0
3	Genetic Loss of Sucrase-Isomaltase Function: Mechanisms, Implications, and Future Perspectives. Volume 16, 31-39	0
2	Objective Evaluation of Chronic Low-Back Pain Using Serum Lipids: The Role of the Doctor-Patient Relationship. 2023 , 2023, 1-8	0
1	COMPARISON OF THERAPY WITH SIMVASTATIN 80 MG AND 120 MG IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLAEMIA. 2001 , 55, 673-675	0